Stock 4BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Bristol-Myers Squibb Company Stock Borsa Italiana

Equities

4BMY

US1101221083

Pharmaceuticals

Real-time Estimate Tradegate
Other stock markets
 07:06:45 2024-05-29 am EDT 		5-day change 1st Jan Change
37.35 EUR -0.63% Intraday chart for Bristol-Myers Squibb Company -4.67% -19.00%
May. 28 Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License MT
May. 27 Bristol Myers: will present data on schizophrenia CF

Financials

Sales 2024 * 46.09B 42.49B Sales 2025 * 46.06B 42.46B Capitalization 82.08B 75.67B
Net income 2024 * -5.41B -4.99B Net income 2025 * 10.22B 9.42B EV / Sales 2024 * 2.63 x
Net Debt 2024 * 39.03B 35.99B Net Debt 2025 * 31.68B 29.2B EV / Sales 2025 * 2.47 x
P/E ratio 2024 *
-15.4 x
P/E ratio 2025 *
7.66 x
Employees 34,100
Yield 2024 *
5.94%
Yield 2025 *
6.24%
Free-Float 69.27%
More Fundamentals * Assessed data

Chart Bristol-Myers Squibb Company

Dynamic Chart

Latest news about Bristol-Myers Squibb Company

Prothena to Receive $80 Million From Bristol-Myers Squibb For PRX019 Global License MT
Bristol Myers: will present data on schizophrenia CF
Bristol Myers: presents over 130 studies at ASCO CF
Bristol-Myers Squibb Unveils Positive Data for KarXT in Schizophrenia Treatment MT
Bristol Myers, Sanofi liability in Hawaii Plavix case grows to $916 million RE
Bristol-Myers Squibb Announces Strategies to Improve Access to Medicines MT
Bristol Myers: 10-year strategy for poor countries CF
Bristol-Myers Squibb Invests in NeoPhore MT
Neophore Limited announced that it has received funding from a group of investors CI
Bristol Myers: national schizophrenia campaign CF
Bristol-Myers Squibb Says US FDA Reassigns Action Date Subcutaneous Nivolumab MT
Bristol Myers: deadline set for subcutaneous Opdivo CF
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab (Nivolumab and Hyaluronidase) CI
Everlasting momentum Our Logo
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma DJ
More news

Latest transcript on Bristol-Myers Squibb Company

Logo Bristol-Myers Squibb Company
Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM
More transcripts

Analyst Recommendations on Bristol-Myers Squibb Company

HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50 MT
ANALYST RECOMMENDATIONS : Tesla, Snap, Alphabet, Microsoft, Anglo American... Our Logo
Goldman Sachs Cuts Bristol-Myers Squibb's Price Target to $56 From $60 MT
Deutsche Bank Adjusts Price Target on Bristol-Myers Squibb to $53 From $55, Keeps Hold Rating MT
Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
More recommendations

Press releases Bristol-Myers Squibb Company

Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma BU
Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms BU
Bristol Myers Squibb to Present Data at the 2024 American Society of Clinical Psychopharmacology Annual Meeting BU
Bristol Myers Squibb Announces Updated Action Date by the U.S. Food and Drug Administration for Subcutaneous Nivolumab AQ
Bristol Myers Squibb Announces 10-Year Strategy to Reach More Patients in Low- and Middle-Income Countries BU
More press releases

News in other languages on Bristol-Myers Squibb Company

Bristol Myers : présentera des données sur la schizophrénie
Bristol Myers : présente plus de 130 études à l'ASCO
USA: BMS et Sanofi condamnés pour défaut d'information sur le Plavix
Bristol Myers : stratégie sur 10 ans pour les pays pauvres
Bristol Myers : campagne nationale sur la schizophrénie
More news

Quotes and Performance

1 day-0.63%
1 week-4.67%
Current month-9.75%
1 month-11.17%
3 months-19.69%
6 months-16.10%
Current year-19.00%
More quotes

Highs and lows

1 week
37.59
Extreme 37.585
38.63
1 month
37.59
Extreme 37.585
42.05
Current year
37.59
Extreme 37.585
50.34
1 year
37.59
Extreme 37.585
61.80
3 years
37.59
Extreme 37.585
80.73
5 years
37.59
Extreme 37.585
80.73
10 years
37.59
Extreme 37.585
80.73
More quotes

Managers and Directors - Bristol-Myers Squibb Company

Managers TitleAgeSince
Christopher Boerner CEO
 Chief Executive Officer 53 15-01-31
David Elkins DFI
 Director of Finance/CFO 55 19-11-19
Greg Meyers CTO
 Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Phyllis Yale BRD
 Director/Board Member 66 19-11-19
Peter Arduini BRD
 Director/Board Member 59 16-03-31
Derica Rice BRD
 Director/Board Member 59 20-08-31
More insiders

Quotes

Date Price Change
24-05-27 37.58 -1.74%
24-05-27 38.25 +0.59%
24-05-24 38.02 -1.57%
24-05-23 38.63 -1.63%
24-05-22 39.27 -0.39%

End-of-day quote Borsa Italiana, May 27, 2024

More quotes

Company Profile

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.
Sector
Pharmaceuticals
Calendar
11:15am - American Society of Clinical Psychopharmacology Meeting - Poster Number: W86
Related indices
S&P 500
More about the company

Income Statement Evolution

More financial data

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
26
Last Close Price
40.49 USD
Average target price
53.19 USD
Spread / Average Target
+31.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.59% 727B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.89% 347B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.66% 319B
ABBVIE INC. Stock AbbVie Inc.
+0.24% 274B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.38% 238B
NOVARTIS AG Stock Novartis AG
+7.15% 204B
ROCHE HOLDING AG Stock Roche Holding AG
-6.13% 203B
AMGEN INC. Stock Amgen Inc.
+4.23% 161B
PFIZER, INC. Stock Pfizer, Inc.
-1.70% 160B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. 4BMY Stock